Danaher Corporation $DHR Shares Purchased by Aptus Capital Advisors LLC

Key Points

• Aptus Capital Advisors LLC increased its stake in Danaher Corporation by 1,396.2% during the first quarter, owning 105,903 shares valued at approximately $21.71 million.
• Danaher reported a quarterly earnings per share of $1.80, exceeding the estimated $1.64, with revenues of $5.94 billion, up 3.4% year-over-year.
• Analysts maintain a consensus rating of "Moderate Buy" for Danaher stock, with an average price target of $247.61.

Aptus Capital Advisors LLC raised its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 1,396.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 105,903 shares of the conglomerate's stock after purchasing an additional 98,825 shares during the period. Aptus Capital Advisors LLC's holdings in Danaher were worth $21,710,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in DHR. GHP Investment Advisors Inc. lifted its holdings in Danaher by 396.0% during the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after purchasing an additional 99 shares in the last quarter. Heck Capital Advisors LLC purchased a new position in Danaher during the fourth quarter valued at $27,000. Sierra Ocean LLC lifted its holdings in Danaher by 116.9% during the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock valued at $29,000 after purchasing an additional 76 shares in the last quarter. Smallwood Wealth Investment Management LLC purchased a new position in shares of Danaher in the first quarter worth about $31,000. Finally, Dunhill Financial LLC lifted its stake in shares of Danaher by 68.4% in the first quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock worth $34,000 after buying an additional 67 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Trading Down 3.4%

DHR stock traded down $7.2480 during trading on Thursday, reaching $204.1520. 3,172,582 shares of the stock were exchanged, compared to its average volume of 4,228,694. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The business has a 50 day moving average price of $200.46 and a 200-day moving average price of $199.62. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $279.90. The firm has a market capitalization of $146.18 billion, a price-to-earnings ratio of 43.44, a P/E/G ratio of 2.96 and a beta of 0.73.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. The business had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business's revenue for the quarter was up 3.4% on a year-over-year basis. During the same period last year, the business earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, research analysts predict that Danaher Corporation will post 7.63 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on DHR. The Goldman Sachs Group decreased their price target on shares of Danaher from $260.00 to $240.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 23rd. Guggenheim reissued a "buy" rating and issued a $250.00 price target on shares of Danaher in a research note on Wednesday, July 23rd. Argus decreased their price target on shares of Danaher from $260.00 to $240.00 in a research note on Wednesday, April 23rd. TD Cowen raised their price target on shares of Danaher from $240.00 to $248.00 and gave the stock a "buy" rating in a research note on Wednesday, April 23rd. Finally, Barclays reissued an "overweight" rating and issued a $225.00 price target (up from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Seventeen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, Danaher presently has an average rating of "Moderate Buy" and an average price target of $247.61.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.